Rengyun Liu
Overview
Explore the profile of Rengyun Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1606
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu G, Xue J, Yu J, Dou Q, Sang Y, Han A, et al.
Thyroid
. 2024 Dec;
35(1):115-119.
PMID: 39682039
Anaplastic thyroid cancer (ATC) is a rare but one of the most lethal types of human cancer. Although increasing evidence demonstrated that ATC tumors had a high mutation burden, little...
2.
Xie Q, Liu X, Liu R, Pan J, Liang J
Mol Cancer
. 2024 Nov;
23(1):252.
PMID: 39529058
PD-1/PD-L1 blockade therapies have displayed extraordinary clinical efficacy for melanoma, renal, bladder and lung cancer; however, only a minority of colorectal cancer (CRC) patients benefit from these treatments. The efficacy...
3.
Li S, Hu G, Chen Y, Sang Y, Tang Q, Liu R
Cancer Cell Int
. 2024 Aug;
24(1):271.
PMID: 39097722
Background: DNA hypermethylation and hotspot mutations were frequently observed in the upstream and core promoter of telomerase reverse transcriptase (TERT), respectively, and they were associated with increased TERT expression and...
4.
Shen X, Tan J, Liu R, Zhu G, Rooper L, Xing M
Mol Oncol
. 2024 Jul;
19(1):248-259.
PMID: 39032134
The significance of the prominent tumor suppressor gene for RAS protein activator-like 1 (RASAL1) could be better understood by combined genetic, clinical, and functional studies. Here, we investigated the oncogenic...
5.
Tang Q, Hu G, Sang Y, Chen Y, Wei G, Zhu M, et al.
Clin Transl Med
. 2024 May;
14(5):e1703.
PMID: 38769666
Background: Hotspot mutations in the promoter of telomerase reverse transcriptase (TERT) gene are the most common genetic variants in hepatocellular carcinoma (HCC) and associated with poor prognosis of the disease....
6.
Chen Y, Sang Y, Li S, Xue J, Chen M, Hong S, et al.
Transl Oncol
. 2024 May;
45:101991.
PMID: 38728872
BRAF or RAS mutation-induced aberrant activation of the mitogen-activated protein kinase (MAPK) pathway is frequently observed in human cancers. As the key downstream node of MAPK pathway, ERK1/2 is as...
7.
Chen Y, Xiao X, Hu G, Liu R, Xue J
J Cancer Res Ther
. 2024 Apr;
20(2):570-577.
PMID: 38687926
Objective: This study aimed to investigate BVD-523 (ulixertinib), an adenosine triphosphate (ATP)-dependent extracellular signal-regulated kinases 1/2 inhibitor, for its antitumor potential in thyroid cancer. Materials And Methods: Ten thyroid cancer...
8.
Sang Y, Hu G, Xue J, Chen M, Hong S, Liu R
Endocrine
. 2024 Feb;
85(1):304-312.
PMID: 38356100
Purpose: Risk stratification based on somatic mutations in TERT promoter and BRAF/RAS has been well established for papillary thyroid cancer (PTC), and there is emerging evidence showed that TERT promoter...
9.
Li S, Xue J, Jiang K, Chen Y, Zhu L, Liu R
Front Oncol
. 2024 Feb;
14:1325345.
PMID: 38313800
The telomerase reverse transcriptase (TERT) is overexpressed and associated with poor prognosis in papillary thyroid cancer (PTC), the most common subtype of thyroid cancer. The overexpression of TERT in PTC...
10.
Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness
Liu R, Zhu G, Tan J, Shen X, Xing M
J Natl Cancer Inst
. 2023 Dec;
116(5):694-701.
PMID: 38113409
Background: BRAF V600E and TERT promoter alterations are core components in current genetics-based risk assessment for precision management of papillary thyroid cancer. It remains unknown whether this approach could achieve...